EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A novel HIV triple broadly neutralizing antibody (bNAb) combination-based passive immunization of infant rhesus macaques achieves durable protective plasma neutralization levels and mediates anti-viral effector functions

Sedem Dankwa, Christina Kosman, Maria Dennis, Elena E Giorgi, Kenneth Vuong, Ioanna Pahountis, Ashley Garza, Christian Binuya, Janice McCarthy, Bryan T Mayer iD, Julia T Ngo, Chiamaka A Enemuo und 14 weitere

PLOS ONE · 11.11.2024 · 19 (11) · e0312411

DOI: 10.1371/journal.pone.0312411 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 11.11.2024. Verfasst von Sedem Dankwa und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Weill Cornell Medicine, New York, NY, United States of America. Hauptthemen laut MEDLINE: Macaca mulatta, Immunization, Passive, HIV Antibodies, HIV Infections. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To eliminate vertical HIV transmission and achieve therapy-free viral suppression among children living with HIV, novel strategies beyond antiretroviral therapy (ART) are necessary. Our group previously identified a triple broadly neutralizing antibody (bNAb) combination comprising of 3BNC117, PGDM1400 and PGT151 that mediates robust in vitro neutralization and non-neutralizing effector functions against a cross-clade panel of simian human immunodeficiency viruses (SHIVs). In this study, we evaluated the safety, pharmacokinetics, and antiviral potency of this bNAb combination in infant rhesus macaques (RMs). We demonstrate that subcutaneous infusion of the triple bNAb regimen was well tolerated in pediatric monkeys and resulted in durable systemic and mucosal distribution. Plasma obtained from passively-immunized RMs demonstrated potent HIV-neutralizing and Fc-mediated antiviral effector functions. Finally, using the predicted serum neutralization 80% inhibitory dilution titer (PT 80 ) biomarker threshold of >200, which was recently identified as a surrogate endpoint for evaluation of the preventative efficacy of bNAbs against mucosal viral acquisition in human clinical trials, we demonstrated that our regimen has PT 80 >200 against a large panel of plasma and breast milk-derived HIV strains and cross-clade SHIV variants. This data will guide the development of combination bNAbs for eliminating vertical HIV transmission and for achieving ART-free viral suppression among children living with HIV.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Macaca mulattaImmunization, PassiveHIV AntibodiesHIV InfectionsSimian Immunodeficiency VirusAntibodies, NeutralizingAnimalsHumansHIV-1Broadly Neutralizing AntibodiesSimian Acquired Immunodeficiency Syndrome

Substanzen

HIV AntibodiesAntibodies, NeutralizingBroadly Neutralizing Antibodies

Autor:innen und Institutionen

  • Department of Pediatrics, Weill Cornell Medicine, New York, NY, United States of America.
  • Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.
  • Department of Surgery, Duke University School of Medicine, Durham, NC, United States of America.
  • Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, United States of America.
  • Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, United States of America.
  • Center for Human Systems Immunology, Duke University, Durham, NC, United States of America.

ORCID-Profile: Bryan T Mayer, Ria Goswami

Förderung

  • NIH HHS
  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • NIH Office of the Director

Zitieren

APA

Dankwa, S., Kosman, C., Dennis, M., Giorgi, E. E., Vuong, K., Pahountis, I., Garza, A., Binuya, C., McCarthy, J., Mayer, B. T., Ngo, J. T., Enemuo, C. A., Carnathan, D. G., Stanfield-Oakley, S., Berendam, S. J., Weinbaum, C., Engelman, K., Magnani, D. M., Chan, C., …, & Goswami, R. (2024). A novel HIV triple broadly neutralizing antibody (bNAb) combination-based passive immunization of infant rhesus macaques achieves durable protective plasma neutralization levels and mediates anti-viral effector functions. PLOS ONE, 19(11), e0312411. https://doi.org/10.1371/journal.pone.0312411

Vancouver

Dankwa S, Kosman C, Dennis M, Giorgi EE, Vuong K, Pahountis I, et al. A novel HIV triple broadly neutralizing antibody (bNAb) combination-based passive immunization of infant rhesus macaques achieves durable protective plasma neutralization levels and mediates anti-viral effector functions. PLOS ONE. 2024;19(11):e0312411. doi:10.1371/journal.pone.0312411

BibTeX
@article{Dankwa2024,
  author = {Dankwa, Sedem and Kosman, Christina and Dennis, Maria and Giorgi, Elena E and Vuong, Kenneth and Pahountis, Ioanna and Garza, Ashley and Binuya, Christian and McCarthy, Janice and Mayer, Bryan T and Ngo, Julia T and Enemuo, Chiamaka A and Carnathan, Diane G and Stanfield-Oakley, Sherry and Berendam, Stella J and Weinbaum, Carolyn and Engelman, Kathleen and Magnani, Diogo M and Chan, Cliburn and Ferrari, Guido and Silvestri, Guido and Amara, Rama R and Chahroudi, Ann and Permar, Sallie R and Fouda, Genevieve G and Goswami, Ria},
  title = {A novel HIV triple broadly neutralizing antibody (bNAb) combination-based passive immunization of infant rhesus macaques achieves durable protective plasma neutralization levels and mediates anti-viral effector functions},
  journal = {PLOS ONE},
  year = {2024},
  volume = {19},
  number = {11},
  pages = {e0312411},
  doi = {10.1371/journal.pone.0312411}
}
Kostenlos starten →